Internal Reference Number: FOI_8943
Date Request Received: 06/10/2025 00:00:00
Date Request Replied To: 21/10/2025 00:00:00
This response was sent via: By Email
Request Summary: Oncology Breast Cancer
Request Category: Researcher
| Question Number 1: I am researching the incidence and treatment of breast cancer. I would greatly appreciate if you could answer the following questions Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies: • Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) • Abemaciclib + Fulvestrant • Alpelisib + Fulvestrant • Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide only • Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Paclitaxel • Atezolizumab • Capivasertib • Capecitabine as a single agent • Carboplatin + Paclitaxel • Elacestrant • Eribulin as a single agent or in combination • Everolimus + Exemestane • Fulvestrant as a single agent • Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) • Palbociclib + Fulvestrant • Parp Inhibitors (Olaparib/Talazoparib) • Pembrolizumab Monotherapy • Pembrolizumab + Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide • Carboplatin + Paclitaxel + Pembrolizumab • Pertuzumab (Perteja) + Trastuzumab (Herceptin) • Phesgo (Pertuzumab + Trastuzumab in a single injection) • Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) • Ribociclib + Fulvestrant • Sacituzumab Govitecan • Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent • Trastuzumab deruxtecan (Enhertu) • Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel • Trastuzumab emtansine (Kadcyla) • Any other active systemic anti-cancer therapy | |
| Answer To Question 1: • Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) 33 • Abemaciclib + Fulvestrant <5 • Alpelisib + Fulvestrant 0 • Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide <5 • Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Paclitaxel 0 • Atezolizumab 0 • Capivasertib 0 • Capecitabine as a single agent 7 • Carboplatin + Paclitaxel <5 • Elacestrant <5 • Eribulin as a single agent or in combination <5 • Everolimus + Exemestane <5 • Fulvestrant as a single agent <5 • Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) 29 • Palbociclib + Fulvestrant <5 • Parp Inhibitors (Olaparib/Talazoparib) <5 • Pembrolizumab Monotherapy <5 • Pembrolizumab + Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide <5 • Carboplatin + Paclitaxel + Pembrolizumab <5 • Pertuzumab (Perteja) + Trastuzumab (Herceptin) <5 • Phesgo (Pertuzumab + Trastuzumab in a single injection) 23 • Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) 21 • Ribociclib + Fulvestrant <5 • Sacituzumab Govitecan <5 • Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent 6 • Trastuzumab deruxtecan (Enhertu) 6 • Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel 13 • Trastuzumab emtansine (Kadcyla) <5 • Any other active systemic anti-cancer therapy 17 | |
| Question Number 2: See attached | |
| Answer To Question 2: Please see attached. To accompany this answer to question 2 please also see the documents listed below:  FOI 8943 Q2 response sheet.pdf | |
| Question Number 3: Does your trust participate in any clinical trials for breast cancer? If so, please provide the name of each trial, and the number of patients taking part. | |
| Answer To Question 3: The Trust currently do not have any clinical trials for breast cancer that are open to recruitment. However, we have participated in a number of trials that are now closed to recruitment, such as: CANDO 3, HERA, AZURE, FAST-Forward, OPTIMA, POSH, TACT, TACT 2 and many others. | |
| Please see Attachments: | |
| To return to the list of all the FOI requests please click here | |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
